若生智能
Drug Database
TE

telmisartan + amlodipine (Micamlo BP / Onduarp / Micamlo AP)

✓ Approved

Astellas Pharma · AGTR1 · 小分子

什么是 telmisartan + amlodipine？

telmisartan + amlodipine 是一种小分子，由Astellas Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Micamlo BP, Onduarp, Micamlo AP
公司Astellas Pharma
药物类别小分子
分子靶点AGTR1, CACNA1C
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Astellas Pharma

作用机制

分子靶点

telmisartan + amlodipine 作用于 2 个分子靶点：

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

telmisartan + amlodipine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedNature nanotechnology2026-06-13

Spatial imaging of water oxidation on single-particle catalysts.

Nie Wei W, Wang Hong-Jia HJ, Gao Yuying Y, Li Deng D et al.

Water oxidation, widely recognized as the kinetic bottleneck of artificial photosynthesis, limits solar fuel efficiency. Despite progress in elucidating reaction mechanisms and theoretical predictions, the dynamic spatial coupling of charge transfer, localized structural motifs and active-site evolution remains unresolved, particularly as identified under operando conditions, obscuring key mechanistic pathways. Here, by integrating operando electrochemical shell-isolated nanoparticle-enhanced Raman spectroscopy with nanoscale electrochemical reaction imaging, we spatially resolve the atomic-scale interplay between hole transfer dynamics and the evolution of water oxidation intermediates that dictates the reaction kinetics on faceted BiVO4 particles. We show that dynamic structural adaption, mediated by multihole accumulation, governs the bifurcation of water oxidation pathways. At low surface hole densities (<0.67 nm-2), both (110) and (010) facets operate under single-hole transfer limitations, stabilizing hydroperoxo and peroxo intermediates, with the (110) facet evolving higher activity. On reaching a critical hole density threshold, the (010) facet evolves to be catalytically superior, exhibiting third-order power-law kinetics driven by the dynamic hole accumulation within Bi-O-V core structures via peroxo intermediates, whereas the (110) facet shifts to accumulate dual oxidizing equivalents, facilitating favourable intramolecular O-O coupling with higher energy demands. This work reveals water oxidation catalysis from static site-centric models to dynamic systems that are governed by hole-mediated structural adaptability, providing design principles for tailoring photocharge-catalyst architectures with atomic-scale precision for solar fuel generation.

PMID 42286220
阅读全文 →
PubMedBMC plant biology2026-06-13

Quantitative trait loci analysis identifying novel genomic regions for off-target dicamba tolerance in soybean [Glycine max (L.) Merr.].

Lee Dongho D, do Nascimento Emanuel Ferrari EF, Acuna-Galindo Andrea A, Harrison Derrick D et al.

Off-target dicamba exposure continues to cause substantial injury and yield loss in non-dicamba-tolerant (non-DT) soybean production areas, creating an urgent need for new cultivars with inherent tolerance to unintended dicamba exposure. To support the development of the soybean breeding pipeline, this study aimed to identify genomic regions associated with natural variation for off-target dicamba tolerance. A bi-parental recombinant inbred line population of 188 F4-derived lines was evaluated across four environments, and quantitative trait loci (QTL) analysis identified six loci on chromosomes 6, 9, 10, 13, 19, and 20, collectively explaining 44.7% of the phenotypic variation. Two loci, qDIC_09.1 and qDIC_13.1, were classified as major QTLs based on their higher phenotypic variation explained (9.9% and 13.5%, respectively). Within the physical intervals of these major QTLs, 43 putative candidate genes were selected based on the functional annotations of differentially expressed genes previously characterized under dicamba exposure in Arabidopsis. These included genes encoding glutathione S-transferase, cytochrome P450, and uridine 5'-diphosphate-glycosyltransferase proteins, which participate in key phases of herbicide detoxification. Of 43 putative candidate genes, gene expression analysis revealed 10 putative candidate genes that are highly expressed in the aboveground tissues in soybean. Nucleotide divergence analyses further revealed a large selective sweep spanning qDIC_13.1, suggesting domestication-driven erosion of potentially beneficial alleles associated with detoxification capacity. The genomic regions and putative candidate genes identified here provide valuable resources for marker development, allele mining, and breeding strategies to improve tolerance to off-target dicamba exposure in non-DT soybean cultivars.

PMID 42286450
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-06-12

Mechanical Activation of Piezo1 Drives Osteoarthritis Through Kdm5c-Mediated Epigenetic Silencing.

Kan Tianyou T, Li Xuran X, Wang Han H, Sun Lin L et al.

Mechanical stress is the most important factor affecting the progression of osteoarthritis (OA), but the mechanism linking mechanical stress to transcriptional repression remains elusive. Here, the study finds that mechanical stress induced epigenetic changes that can serve as therapeutic targets for osteoarthritis. By using Piezo1 conditional knockout (Col2a1CreERT; Piezo1flox/flox) mice, it was found that Piezo1 activation by excessive mechanical stress can trigger chromatin remodeling via cytoskeletal force transmission, promoting the histone demethylase Kdm5c-mediated epigenetic silencing. Kdm5c in turn erases H3K4me3 marks from promoters of cartilage-anabolic genes Col2a1 and Runx3, silencing their expression. Genetic ablation of Kdm5c rescues mechanical stress-induced cartilage degradation. Through drug repurposing, the study identifies telmisartan as a direct Kdm5c inhibitor that blocks this pathway and demonstrates disease-modifying efficacy in mouse OA models and human cartilage explants. These results establish the Piezo1-Kdm5c axis as a fundamental driver of OA and position telmisartan as a mechano-epigenetic therapy with immediate translational potential.

PMID 42284507
阅读全文 →
PubMedCancers2026-06-12

Clinical Value of a Novel Apparent Diffusion Coefficient-Based Bi-Color Map for Detecting Clinically Significant Prostate Cancer: A Retrospective Study.

Okada Mitsuo M, Araki Yoichi Y, Hirasawa Yosuke Y, Nagao Go G et al.

Background: Minimum apparent diffusion coefficient (ADC) values are independent predictors of clinically significant prostate cancer (csPC). We developed a novel ADC-based bi-color map and evaluated its utility for identifying lesions suspicious for csPC. Methods: We retrospectively analyzed 108 targeted prostate biopsy cases and 93 radical prostatectomy cases. In the biopsy cohort, we assessed the association between ADC-based bi-color map positivity and csPC in lesions with a Prostate Imaging-Reporting and Data System (PI-RADS) score ≥ 3. In the prostatectomy cohort, we evaluated additional color map-positive lesions not categorized as PI-RADS ≥ 3 on preoperative MRI. Results: In the biopsy cohort, 118 lesions were positive on the ADC-based bi-color map, including lesions outside PI-RADS ≥ 3 categories. Among 157 lesions with a PI-RADS score ≥ 3, csPC was detected in 65 lesions (41.4%). Of these lesions, 70 (44.6%) were positive on the bi-color map, and csPC was identified in 49 (70.0%). The added value of the bi-color map was most evident in PI-RADS 4 lesions, where csPC detection rates were significantly higher in color map-positive than in color map-negative lesions (74.4% vs. 23.3%). In the prostatectomy cohort, 215 lesions were positive on the bi-color map, and csPC was confirmed pathologically in 126 lesions (58.6%). Among 82 color map-positive lesions not classified as PI-RADS ≥3, 55 (67.1%) corresponded to csPC. Conclusions: The ADC-based bi-color map may improve lesion highlighting and risk stratification for csPC and help identify suspicious lesions overlooked on conventional MRI assessment.

PMID 42279378
阅读全文 →
PubMedThe journal of physician assistant education : the official journal of the Physician Assistant Education Association2026-06-12

Leveraging Technology for Continuous Programmatic Self-Assessment.

Taylor Holland H

The Accreditation Review Commission on Education for the Physician Assistant requires programs to implement ongoing self-assessment processes using numerous measures to evaluate their effectiveness, entailing data collection, critical analysis, application of results, and the formulation of conclusions. Developing, implementing, and maintaining a robust ongoing self-assessment process is challenging for physician assistant/associate educators due to competing complexities, time limitations, overwhelming amounts of data, and a lack of training and/or adequate resources, which impact program success and faculty and staff stress. Recent technological advances, such as business intelligence (BI) software, may influence faculty and staff experiences in programmatic self-assessment. A survey was used to quantitatively and qualitatively gauge faculty and staff experiences and perceptions of using BI technology in the study program's self-assessment process. Survey items focused on data management, usability, task management, faculty and staff stress, and overall satisfaction. Faculty and staff reported positive perceptions overall. Favorable narratives emerged related to their experiences using BI tools for self-assessment activities within the study program. Respondents recommend these tools to other programs and offer valuable insight to ensure successful implementation. The findings of this single-program study suggest that the use of BI technology may contribute favorably to faculty and staff experiences in programmatic self-assessment. However, further studies are needed to correlate a relationship and explore generalizability.

PMID 42283615
阅读全文 →
PubMedCureus2026-06-12

Improving Breast Cancer Screening Coverage in Primary Healthcare: A Quality-Improvement Study (2023-2025).

AlAwadh Salwa A SA, AlShammari Razan Z RZ, AlJohi Hawra A HA, Aseeri Rawan M RM et al.

Organized breast cancer screening reduces mortality; however, coverage within our primary healthcare (PHC) network was substantially below benchmarks. Barriers included limited awareness, fragmented workflows, suboptimal use of electronic systems, and constrained diagnostic capacity. Screening delivery relied on opportunistic identification rather than systematic recall, resulting in missed opportunities, limited performance monitoring, and prolonged diagnostic pathways. This study aimed to increase breast cancer screening coverage among eligible women aged 40-69 years attending PHC clinics from 1.0% in August 2023 to at least 76% by September 2025 through: (1) systematic identification of eligible women using electronic health records (EHR)-based prompts and recall systems; (2) increased completion of screening mammograms; (3) timely diagnostic follow-up (≤14 days); and (4) minimal disruption to clinical workflow. A quality-improvement (QI) initiative was conducted from August 2023 to October 2024 using the Institute for Healthcare Improvement Model for Improvement and sequential Plan-Do-Study-Act (PDSA) cycles. A multi-disciplinary team reviewed weekly and monthly reports tracking mammography requests, completions, Breast Imaging Reporting and Data System (BI-RADS) results, and waiting times. Although active implementation concluded in October 2024, outcomes were monitored through September 2025 to assess sustainability. Four PDSA cycles addressed as follows: (1) staff awareness and readiness, (2) structured patient recall using electronic health record-generated eligibility lists and outreach, (3) performance transparency via dashboards and feedback, and (4) workflow integration with periodic audits to support sustainability. The primary outcome was screening coverage. Secondary outcomes included BI-RADS distribution and confirmed malignancies. Balancing measures were mammography waiting time and physician perceptions. Documented screening coverage increased from 1.0% (n=49) in August 2023 to 70% (n≈3,400 of 4,857 eligible women) by September 2025. During the project period, a total of 1,652 screening mammograms were completed. Among completed mammograms, 68.2% (n=1,127) were BI-RADS 1-2, 18.9% (n=312) BI-RADS 0, 11.6% (n=192) BI-RADS 3, and 1.3% (n=21) BI-RADS 4-5, yielding 11 confirmed malignancies. Waiting times improved following capacity adjustments. Physician survey responses (n=36) indicated good acceptability and perceived feasibility within routine practice. A multi-component, data-driven QI strategy integrated into PHC workflows was feasible and associated with substantial and sustained improvement in breast cancer screening coverage while maintaining timely diagnostic follow-up.

PMID 42281707
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多telmisartan + amlodipine